Skip to main content
SpringerLink
Log in

Acute myeloid leukemia in the elderly: biological features and search for adequate treatment

  • Review
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

AML in elderly patients is a heterogeneous disease which is characterized by a number of unfavorable features such as development, cytogenetics, blast cell differentiation, and poor treatment response. Specifically, the association between a higher incidence of unfavorable cytogenetic abnormalities in elderly patients and poor prognosis has been well documented. Low treatment response may be due to the specific biology of AML in this patient group, but also to host-specific factors such as higher treatment-related morbidity and mortality. Treatment tolerance cannot be judged on grounds of chronological age alone; risk factor analysis with regard to performance status, organ function, and underlying systemic disease need to be considered as well. For effective induction treatment in elderly patients, instant and intensive chemotherapy appears to be necessary, while delayed treatment or administration of supportive care alone provide unsatisfactory results. Standard-dose ara-C/anthracycline-containing regimens are the treatment of choice in patients with good performance status. However, patients with a WHO grading of >3 might rather benefit from reduced regimens such as low-dose ara-C. At present, greatest improvement of AML treatment in elderly patients can be expected from an improvement of supportive care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderson RL, Bagby GC, Richert-Boe K, Magenis RE, Koler AD (1981) Therapy-related preleukemic syndrome. Cancer 47: 1867–1871

    Google Scholar 

  2. Anderson S, Brenner BM (1986) Effects of aging on the renal glomerolus. Am J Med 80: 435–442

    Google Scholar 

  3. Arlin Z, Case DC jr, Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K, Lederle Cooperative Group (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4: 177–183

    Google Scholar 

  4. Balducci L, Parker M, Sexton W, Tantranond P (1989) Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol 16: 76–84

    Google Scholar 

  5. Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Heller G, Young CW, Clarkson BD (1989) Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol 16 [Suppl 2]: 30–34

    Google Scholar 

  6. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi C, Gorischeck C, Muhm M, Sillaber Ch, Haas O, Vieder L, Maurer D, Schulz G, Speiser W, Geissler K, Kier P, Hinterberger W, Lechner K (1991) Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo myeloid leukemia. Blood 77: 700–711

    Google Scholar 

  7. Bloomfield CD, Theologides A (1973) Acute granulocytic leukemia in elderly patients. JAMA 226: 1190–1193

    Google Scholar 

  8. Bolwell BJ, Cassileth PA, Gale RP (1987) Low-dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1: 575–579

    Google Scholar 

  9. Brandt L, Nilsson PG, Mitelman F (1979) Trends in incidence of acute leukemia. Lancet 1: 1069

    Google Scholar 

  10. Brincker H (1985) Estimates of overall treatment results in acute non-lymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 69: 5–11

    Google Scholar 

  11. Buechner T, Hiddemann W (1990) Treatment strategies in acute myeloid leukemia (AML). Blut 60: 61–67

    Google Scholar 

  12. Buechner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, König HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Löffler H, Gassmann W, Hellriegel KP, Fülle H, Lunscken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen KM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Köppler H, Zurborn KH, Ranft K, Thiel E, Heinecke A (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589

    Google Scholar 

  13. Buzdar AU, Marcus C, Smith TL, Blumenschein GR (1985) Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55: 2761–2765

    Google Scholar 

  14. Cadman E, Capizzi R, Bertino J (1977) Acute nonlymphocytic leukemia. A delayed complication of Hodgkin's disease therapy. Analysis of 109 cases. Cancer 40: 1280–1296

    Google Scholar 

  15. Capizzi RL, Poole M, Cooper MR, Richards FH (1984) Treatment of poor-risk acute leukemia with sequential high-dose ara-C and asparaginase. Blood 63: 694–700

    Google Scholar 

  16. Capizzi RL, Powell BL, Cooper MR, Stuart JJ, Muss HB, Richards F II, Jackson DV, White DR, Spurr CL, Zekan PJ, Cruz JM, Craig JB (1985) Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia. Semin Oncol 12 [Suppl 3]: 105–113

    Google Scholar 

  17. Capizzi RL, Davis R, Powell B, Cuttner J, Ellison RR, Cooper MR, Dillman R, Major WB, Dupre E, McIntyre OR (1988) Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed myelogenous leukemia — a Cancer and Leukemia Group B study. J Clin Oncol 6: 499–508

    Google Scholar 

  18. Casazza AM, Bertazzoli C, Pratesi G, Bellini O, Di Marco A (1979) Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin (4-DMD) in mice. Proc Am Assoc Cancer Res 20: 16

    Google Scholar 

  19. Cassileth PA (1990) Intensive therapy in elderly patients with acute myeloid leukemia. J Clin Oncol 8: 937

    Google Scholar 

  20. Cassileth PA, Begg CB, Bennett JM, et al. (1984) A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 63: 843–847

    Google Scholar 

  21. Champlin R, Gale RP, Elashoff R, Jacobs A, Boccia R, Foon K (1984) Prolonged survival in acute myelogenous leukemia without maintenance chemotherapy. Lancet 1: 894–896

    Google Scholar 

  22. Cheson BD, Jasperse DM, Simon R, Friedman MA (1986) A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 4: 1857–1864

    Google Scholar 

  23. Cohen JL (1986) Pharmacokinetic changes in aging. Am J Med 80 [Suppl 5A]: 31–38

    Google Scholar 

  24. Damon LE, Mass R, Linker CA (1989) The association between high-dose cytarabine neurotoxicity and renal insufficiency. J Clin Oncol 7: 1563–1568

    Google Scholar 

  25. Degos L, Castaigne S, Tilly H, Sigaux F, Daniel MT (1985) Treatment of leukemia with low-dose ara-C: a study of 160 cases. Semin Oncol 12 [Suppl 3]: 196–199

    Google Scholar 

  26. Delmer A, Marie JP, Thevenin D, Cadiou M, Viguie F, Zittoun R (1988) Multivariate analysis of prognostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties. J Clin Oncol 7: 738–746

    Google Scholar 

  27. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1982) Causes of initial remission failure in acute myelogenous leukemia. Blood 60: 309–315

    Google Scholar 

  28. Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W (1990) Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4: 95–99

    Google Scholar 

  29. Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB, Gutterman JU (1990) Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 75: 1766–1769

    Google Scholar 

  30. Fearon ER, Burke PJ, Schiffer CA, Zehnbauer BA, Vogelstein B (1986) Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med 315: 15–24

    Google Scholar 

  31. Fenaux P, Preudhomme C, Lai JL, Morel P, Beuscart R, Bauters F (1989) Cytogenetics and their prognostic value in de novo acute myeloid leukemia: a report on 283 cases. Br J Haematol 73: 61–67

    Google Scholar 

  32. Fenaux P, Lai JL, Gardin C, Bauters F (1990) Cytogenetics are a predictive factor of response to low-dose ara-C in acute myelogenous leukemia (AML) in the elderly. Leukemia 4: 312

    Google Scholar 

  33. Fialkow PJ, Singer JW, Adamson JW, Vaidya K, Dow LW, Ochs J, Moohr JW (1981) Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood 57: 1068–1073

    Google Scholar 

  34. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, Dow LW, Najfeld V, Veith R (1987) Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 317: 468–473

    Google Scholar 

  35. Foon KA, Zighelboim J, Yale C, Gale RP (1981) Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 58: 467–470

    Google Scholar 

  36. Foucar K, McKenna RW, Bloomfield CD, Bowers TK, Brunning RD (1979) Therapy-related leukemia. A panmyelosis. Cancer 43: 1285–1296

    Google Scholar 

  37. Gale RP, Foon KA, Cline MJ, Zighelboim J, and the UCLA Acute Leukemia Study Group (1981) Intensive chemotherapy for acute myelogenous leukemia. Ann Intern Med 94: 753–757

    Google Scholar 

  38. Ganser A, Voelkers B, Greher J, Ottmann OG, Walther F, Becher R, Bergmann L, Schulz G, Hoelzer D (1989) Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes — a phase I/II trial. Blood 73: 31–37

    Google Scholar 

  39. Ganz PA (1991) Survival in acute leukemia in elderly patients. J Am Geriatr Soc 39: 102–107

    Google Scholar 

  40. Glucksberg H, Cheever MA, Farewell VT, Fefer A, Sale GE, Thomas ED (1981) High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults. Cancer 48: 1073–1081

    Google Scholar 

  41. Greenblatt DJ, Sellers EM, Shader RI (1982) Drug disposition in old age. N Engl J Med 306: 1081–1088

    Google Scholar 

  42. Griffin JD, Young D, Herrmann F, Wiper D, Wagner K, Sabbath KD (1986) Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 67: 1448–1453

    Google Scholar 

  43. Groupe Francais de Morphologie Hematologique (1987) French registry of acute leukemia and myelodysplastic syndromes. Cancer 60: 1385–1394

    Google Scholar 

  44. Harousseau JL, Castaigne S, Milpied N, Marty M, Degos L (1984) Treatment of acute non-lymphoblastic leukemia in elderly patients. Lancet 1: 288

    Google Scholar 

  45. Hasle H (1990) Cerebellar toxicity during cytarabine therapy associated with renal insufficiency. Cancer Chemother Pharmacol 27: 76–78

    Google Scholar 

  46. Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM, Adelstein DJ, Brown RA, Coccia PF, Strandjord S, Mazza JJ, Fay J, Phillips GL (1987) Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 5: 927–932

    Google Scholar 

  47. Hoff DD von, Rozencweig M, Piccart M (1982) The cardiotoxicity of anticancer agents. Semin Oncol 9: 23–33

    Google Scholar 

  48. Jensen KM, Ahlbom G (1985) Low-dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemia. Scand J Haematol 34: 261–263

    Google Scholar 

  49. Kahn SB, Begg CB, Mazza JJ, Bennett JM, Bonner H, Glick JH (1984) Full-dose versus attenuated-dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 2: 865–870

    Google Scholar 

  50. Kantarjian HM, Barlogie B, Keating MJ, Hall RR, Smith TL, McCredie KB, Freireich EJ (1985) Pretreatment cytokinetics in acute myelogenous leukemia. J Clin Invest 76: 319–324

    Google Scholar 

  51. Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Freireich EJ (1980) Factors related to length of complete remission in adult acute leukemia. Cancer 45: 2017–2029

    Google Scholar 

  52. Keating MJ, McCredie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ (1981) Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 58: 584–591

    Google Scholar 

  53. Keating MJ, Smith TL, McCredie KB, Bodey GP, Hersh EM, Gutterman JU, Gehan E, Freireich EJ (1981) A four-year experience with anthracycline, cytosine arabinoside, vincristine, and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 47: 2779–2788

    Google Scholar 

  54. Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Freireich EJ (1982) A prognostic factor analysis for use in development of predictive models for response in adult leukemia. Cancer 50: 457–465

    Google Scholar 

  55. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res 11: 119–133

    Google Scholar 

  56. Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T (1987) Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol 78 [Suppl 1]: 120–126

    Google Scholar 

  57. Koeffler P, Rowley J (1985) Therapy-related acute non-lymphocytic leukemia in neoplastic diseases of the blood. In: Canellos G, Kyle R, Schiffer C (eds) Churchill Livingstone, New York, pp 357–384

    Google Scholar 

  58. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ (1981) Central nervous system toxicity of highdose systemic cytosine arabinoside. Cancer 48: 2577–2582

    Google Scholar 

  59. Loewenberg B, Zittoun R (1990) Intensive therapy in elderly patients with acute myeloid leukemia. J Clin Oncol 8: 937

    Google Scholar 

  60. Loewenberg B, Zittoun R, Kerkhofs H, Jehn U, Abels J, Debusscher L, Cauchie C, Peetermans M, Solbu G, Suciu S, Stryckmans P (1989) On the value of intensive remission-induction chemothearpy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase-III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7: 1268–1274

    Google Scholar 

  61. Mertelsmann R, Thaler HT, To L, Gee TS, McKenzie S, Schauer P, Friedman A, Arlin Z, Cirrincione C, Clarkson B (1980) Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56: 773–781

    Google Scholar 

  62. Metcalf D (1990) The colony-stimulating factors. Discovery, development, and clinical applications. Cancer 65: 2185–2195

    Google Scholar 

  63. Michels SD, McKenna RW, Arthur DC, Brunning AD (1985) Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 65: 1364–1372

    Google Scholar 

  64. Mitelman F, Brandt L, Nilsson PG (1978) Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. Blood 52: 1229–1237

    Google Scholar 

  65. Moore MAS (1990) Hematopoietic growth factors in cancer. Cancer 65: 836–844

    Google Scholar 

  66. National Institute of Health (1974) Publication no 75: 637

  67. Peterson BA, Bloomfield CD (1977) Treatment of acute non-lymphocytic leukemia in elderly patients. Cancer 40: 647–652

    Google Scholar 

  68. Petti MC, Mandelli F, Avvisati G, Covelli A, Amadori S, Liso V, Leone G, de Laurenzi A, Leoni P, Neri A, Grignani F, Torlontano G, Deriu L, Caronia F (1989) High-dose ara-C (Hi-DAC) plus asparaginase in elderly patients with acute non-lymphocytic leukemia: a pilot multicentric study by the Italian cooperative group GIMEMA. Eur J Haematol 42: 24–31

    Google Scholar 

  69. Powell BL, Capizzi RL, Muss HB, Bearden JD, Lyerly ES, Rosenbaum DL, Morgan TM, Richards F, Jackson DV, White DR, Nelson EC, Butler WM, Zekan PJ, Cruz JM, Cooper MR, Buss DH, Spurr CL (1989) Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia 3: 23–28

    Google Scholar 

  70. Preisler H, Davis RB, Kirshner J, Dupre E, Richards F III, Hoagland C, Kopel S, Levy RN, Carey R, Schulman P, Gottlieb AJ, McIntyre OR, Cancer and Leukemia Group B (1987) Comparison of three remission induction regimens and two post-induction strategies for treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 69: 1441–1449

    Google Scholar 

  71. Preisler HD, Raza A, Barcos M, Azarnia N, Larson R, Walker I, Browman M, Grunwald H, D'Arrigo P, Doeblin T, Bloom M, Stein A, Logue G, Goldberg J, Kirshner J, Gottlieb A, Bennett J (1987) High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a leukemia intergroup study. J Clin Oncol 5: 75–82

    Google Scholar 

  72. Preisler HD, Raza A, Early A, Kirshner J, Brecher M, Freeman A, Rystum Y, Azarnia N, Priore R, Sandberg A, Block AM, Browman G, Walker I, Benjer A, Miller K, D'Arrigo P, Doeblin T, Stein A, Bloom M, Logue G, Rustagi P, Barcos M, Larson R, Joyce R (1987) Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 5: 722–730

    Google Scholar 

  73. Preisler HD, Anderson K, Rai K, Cuttner J, Yates J, DuPre E, Holland JF (1989) The frequency of long-term remission in patients with acute myelogenous leukemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow-up time of 6 years. Br J Haematol 71: 189–194

    Google Scholar 

  74. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper MR, Haurani F, Hutchinson JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanan SV, Blom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK (1981) Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 58: 1203–1212

    Google Scholar 

  75. Raza A, Preisler HD, Day R, Yasin Z, White M, Lykins J, Kukla C, Barcos M, Bennett J, Browman G, Goldberg J, Grunwald H, Larson R, Vardiman J, Vogler R (1990) Direct relationship between remission duration in acute myeloid leukemia and cell-cycle kinetics: a leukemia intergroup study. Blood 76: 2191–2197

    Google Scholar 

  76. Rees JKH, Swirsky D, Gray RG, Hayhoe FGJ (1986) Principal results of the Medical Research Council's 8th acute myeloid leukemia trial. Lancet 2: 1236–1241

    Google Scholar 

  77. Report of the Med Res Council's Working Party on Leukemia in Adults (1974) Treatment of acute myeloid leukemia with daunorubicin, cytosine arabinoside, mercaptopurine, 1-asparaginase, prednisone, and thioguanine: results of treatment with five multiple-drug schedules. Br J Haematol 27: 373–389

    Google Scholar 

  78. Robert J, Hoerni B (1983) Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 43: 4467–4469

    Google Scholar 

  79. Rowley JD (1981) Association of specific chromosome abnormalities with type of acute leukemia and with patient age. Cancer Res 41: 3407–3410

    Google Scholar 

  80. Rowley JD, Alimena G, Garson OM, Hagemeijer A, Mitelman F, Prigogina EL (1982) A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. Blood 59: 1013–1022

    Google Scholar 

  81. Samuels BL, Larson RA, Le Beau MM, Daly KM, Bitter MA, Vardiman JW, Barker CM, Rowley JD, Golomb HM (1988) Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 2: 79–83

    Google Scholar 

  82. Sandberg AA (1986) The chromosomes in human leukemia. Semin Hematol 23: 201–217

    Google Scholar 

  83. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JA (1989) Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73: 263–270

    Google Scholar 

  84. Sebban C, Archimbaud E, Coiffier B, Guyotat D, Treille-Ritouet D, Maupas J, Fiere D (1988) Treatment of acute myeloid leukemia in elderly patients. Cancer 61: 227–231

    Google Scholar 

  85. Swirsky DM, De Bastos M, Parish SE, Rees JKH (1986) Features affecting outcome during remission induction of acute myeloid leukemia in 619 adult patients. Br J Haematol 64: 435–453

    Google Scholar 

  86. Tallman MS, Appelbaum FR, Amos D, Goldberg RS, Livingston RB, Mortimer J, Weiden PL, Thomas ED (1987) Evaluation of intensive postremission chemotherapy for adults with acute non-lymphocytic leukemia using high-dose cytosine arabinoside with 1-asparaginase and amsacrine with etoposide. J Clin Oncol 5: 918–926

    Google Scholar 

  87. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise P-Y, Tertian G, Desablens B, Henry-Amar M, Degos L (1990) Lowdose cytarabine versus intensive chemotherapy in the treatment of nonlymphocytic leukemia in the elderly. J Clin Oncol 8: 272–279

    Google Scholar 

  88. Tricot G, Boogaerts MA, Vlietinck R, Emonds MP, Verwilghen RL (1987) The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukemia. Br J Haematol 66: 37–44

    Google Scholar 

  89. Tucker J, Thomas AE, Gregory WM, Ganesan TS, Malik STA, Amess JAL, Lim J, Willis L, Rohatiner AZS, Lister TA (1990) Acute myeloid leukemia in elderly adults. Haematol Oncol 8: 13–21

    Google Scholar 

  90. Unverferth DV, Magorien RD, Leier CV, Balcerzak SP (1982) Doxorubicin cardiotoxicity. Cancer Treat Rev 9: 149–164

    Google Scholar 

  91. Vardiman JW, Coelho A, Golomb HM, Rowley J (1983) Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia. Am J Clin Pathol 79: 525–530

    Google Scholar 

  92. Villani F, Galimberti M, Comazzi R, Crippa F (1989) Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin). Eur J Cancer Clin Oncol 25: 13–18

    Google Scholar 

  93. Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ (1987) Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer 60: 149–155

    Google Scholar 

  94. Wiernik PH, Case DC, Periman PO, Arlin ZA, Weitberg AB, Ritch PS, Todd MB (1989) A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. Semin Oncol 16 [Suppl 2]: 25–29

    Google Scholar 

  95. Willemze R, Jager U, Jehn U, Stryckmans P, Bury J, Suciu S, Solbu G, Zittoun R, Burghouts J, Löwenberg B, Abels J, Cauchie C (1988) Intermediate- and high-dose ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC leukemia cooperative group phase-II study. Eur J Cancer Clin Oncol 24: 1721–1725

    Google Scholar 

  96. Winkelman MD, Hines JD (1983) Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol 14: 520–527

    Google Scholar 

  97. Wolff SN, Herzig RH, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B, Herzig GP (1989) High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 7: 1260–1267

    Google Scholar 

  98. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60: 454–462

    Google Scholar 

  99. Yunis JJ, Brunning RD, Howe RB, Lobell M (1984) High-resolution chromosomes as an independent prognostic indicator in adult acute nonlymphocytic leukemia. New Engl J Med 311: 812–818

    Google Scholar 

  100. Zittoun R, Cadiou M, Bayle C, Suciu S, Solbu G, Hayat M, and the EORTC Leukemia and Hematosarcomas Group (1984) Prognostic value of cytologic parameters in acute myelogenous leukemia. Cancer 53: 1526–1532

    Google Scholar 

  101. Zittoun R, Jehn U, Fiere D, Haanen C, Löwenberg C, Willemze R, Abels J, Bury J, Peetermans M, Hayat M, Suciu S, Solbu G, Stryckmans P (1989) Alternating versus repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase-III study (AML6) of the EORTC leukemia cooperative group. Blood 73: 896–906

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, University of Munich, Klinikum Grosshadern, Marchioninistrasse 15, W-8000, Munich 70, Germany

    V. Heinemann & U. Jehn

Authors
  1. V. Heinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Jehn
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heinemann, V., Jehn, U. Acute myeloid leukemia in the elderly: biological features and search for adequate treatment. Ann Hematol 63, 179–188 (1991). https://doi.org/10.1007/BF01703440

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01703440

Keywords

Search

Navigation